Completed PHASE2 INTERVENTIONAL 4-arm NCT02804763

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

Sponsor: UCB Biopharma S.P.R.L.

Conditions Systemic Lupus Erythematosus (SLE)

Interventions Dapirolizumab pegol (DZP) Placebo

Updated 23 times since 2017 Last updated: Jun 7, 2021 Started: Jun 2, 2016 Primary completion: May 31, 2018 Completion: Nov 19, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Systemic Lupus Erythematosus (SLE) and is currently completed. UCB Biopharma S.P.R.L. leads this study, which shows 23 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

23 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Oct 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 18 earlier versions

Jan 2021 — Sep 2021 [monthly]

Completed PHASE2
Jan 2020 — Jan 2021 [monthly]

Completed PHASE2
Aug 2019 — Jan 2020 [monthly]

Completed PHASE2
Jul 2019 — Aug 2019 [monthly]

Completed PHASE2
Mar 2019 — Jul 2019 [monthly]

Completed PHASE2
Feb 2019 — Mar 2019 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jul 2018 — Feb 2019 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2018 — Feb 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE2
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Sep 2017 — Oct 2017 [monthly]

Recruiting PHASE2
Jun 2017 — Sep 2017 [monthly]

Recruiting PHASE2
May 2017 — Jun 2017 [monthly]

Recruiting PHASE2
Apr 2017 — May 2017 [monthly]

Recruiting PHASE2
Feb 2017 — Apr 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Biopharma S.P.R.L.

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amarillo, United States , Arequipa, Peru , Atlanta, United States , Barcelona, Spain , Barranquilla, Colombia , Birmingham, United States , Bogotá, Colombia , Brasov, Romania , Bucaramanga, Colombia and 54 more locations